# Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

> **NCT03288324** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 13 (actual)

## Conditions studied

- Cutaneous Lupus
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT03288324
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2022-11-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288324, "Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03288324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*